| 67.28 2.31 (3.56%) | 11-29 10:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 80.89 | 1-year : | 94.48 |
| Resists | First : | 69.26 | Second : | 80.89 |
| Pivot price | 63.85 |
|||
| Supports | First : | 62.56 | Second : | 58.43 |
| MAs | MA(5) : | 65.96 |
MA(20) : | 64.06 |
| MA(100) : | 75.77  |
MA(250) : | 71.48 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 71.2 |
D(3) : | 68.2 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 100.76 | Low : | 43.68 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EXAS ] has closed below upper band by 14.9%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 65.52 - 65.96 | 65.96 - 66.32 |
| Low: | 62.73 - 63.16 | 63.16 - 63.51 |
| Close: | 64.34 - 65.04 | 65.04 - 65.62 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Tue, 28 Nov 2023
EXAS Quantitative Stock Analysis - Nasdaq
Tue, 28 Nov 2023
Top Research Reports for Microsoft, Broadcom & Wells Fargo - Nasdaq
Tue, 28 Nov 2023
Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain - Yahoo Finance
Tue, 21 Nov 2023
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech ... - Nasdaq
Mon, 20 Nov 2023
2 Revolutionary Stocks That Could Turn $1,000 Into $2,000 by 2030 - The Motley Fool
Fri, 17 Nov 2023
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 181 (M) |
| Shares Float | 179 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 88.7 (%) |
| Shares Short | 7,570 (K) |
| Shares Short P.Month | 7,580 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.26 |
| Profit Margin | -11.8 % |
| Operating Margin | -10.4 % |
| Return on Assets (ttm) | -3.5 % |
| Return on Equity (ttm) | -9.1 % |
| Qtrly Rev. Growth | 20.1 % |
| Gross Profit (p.s.) | 8.34 |
| Sales Per Share | 13.32 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 139 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -42.83 |
| PEG Ratio | -0.5 |
| Price to Book value | 3.92 |
| Price to Sales | 5.07 |
| Price to Cash Flow | 88.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|